

Appendix

Supplemental Materials

Increasing Use of Allogeneic Hematopoietic Cell Transplantation in Patients Age 70 Years and Older in the United States

Muffly L. et al

Table A: Detailed Characteristics of AML Patients 70 Years and Older Transplanted between 2008 and 2013.

Characteristics of patients	N (%)
Number of patients	120
Number of centers	46
Age	
Median (range), years	72 (70 - 81)
70-74	105 (88)
75-79	14 (12)
≥ 80	1 (<1)
Sex	
Male	83 (69)
Female	37 (31)
Karnofsky score	
<90%	42 (35)
90-100%	77 (64)
Unknown	1 (<1)
HCT-CI	
0	28 (23)
1-2	32 (27)
≥ 3	60 (50)
Cytogenetics	
Favorable	5 (4)
Intermediate	84 (70)
Poor	30 (25)
Not tested	1 (<1)
FLT-3 mutation	
Mutated	10 (8)
Wild type	59 (49)
Unknown	51 (43)
Disease status prior to transplant	
Early disease	64 (53)
Intermediate disease	19 (16)
Advanced disease	37 (31)
Time from diagnosis to transplant, median (range), months	7 (2 - 49)
AML in remission (any CR)	
No	37 (31)
Yes	83 (69)
Donor type for analysis	

Characteristics of patients	N (%)
HLA-matched related	19 (16)
HLA-mismatched related	8 (7)
HLA-matched URD	54 (45)
HLA-mismatched URD	10 (8)
URD HLA match unknown	4 (3)
UCB	25 (21)
Unrelated donor age, median (range), years	29 (19 - 52)
18-30	37 (54)
31-40	17 (25)
41-50	7 (10)
51-61	1 (1)
Missing	6 (9)
D-R sex match	
M-M	46 (38)
M-F	20 (17)
F-M	28 (23)
F-F	11 (9)
Missing	15 (13)
D-R CMV status	
+/+	24 (20)
+/-	12 (10)
-/+	45 (38)
-/-	19 (16)
Missing	20 (17)
Graft source	
Bone marrow	9 (8)
Peripheral blood	86 (72)
Umbilical cord blood	25 (21)
Conditioning regimen intensity	
Myeloablative	11 (9)
RIC	69 (58)
NMA	40 (33)
Conditioning regimen	
Flu/Bu+/-other	36 (30)
Flu/Mel+/-other	18 (15)
Flu/TBI+/-other	52 (43)
Bu-based	4 (3)
Flu/Cy+/-other	1 (<1)
TBI/TLI+/-other	8 (7)
Others	1 (<1)
GVHD prophylaxis	
T-cell depletion	5 (4)
CNI+MMF+/-other	60 (50)
CNI+MTX+/-other	42 (35)
CNI+/-other (no MMF or MTX)	7 (6)
Post-Cy+/-other	5 (4)
Other	1 (<1)
Year of transplant	
2008-2011	63 (53)
2012-2013	57 (48)

Characteristics of patients	N (%)
Median follow-up of survivors, range, months	30 (6 - 73)


Supplementary Figure 1A: Cumulative incidence of transplant related mortality of patients 70 years and older with early or intermediate AML and MDS, and recipients of an allogeneic hematopoietic cell transplantation from 2008 to 2013 stratified according to HCT CI.

Supplementary Figure 1B: Probability of overall survival of patients 70 years and older with early or intermediate AML and MDS, and recipients of an allogeneic hematopoietic cell transplantation from 2008 to 2013 stratified according to HCT CI.


Supplementary Figure 1C: Cumulative incidence of transplant related mortality of patients 70 years and older with advanced AML and MDS, and recipients of an allogeneic hematopoietic cell transplantation from 2008 to 2013 stratified according to HCT CI.

Supplementary Figure 1D: Probability of overall survival of patients 70 years and older with advanced AML and MDS, and recipients of an allogeneic hematopoietic cell transplantation from 2008 to 2013 stratified according to HCT CI.


Supplementary Figure 1A



Supplementary Figure 1B



Supplementary Figure 1C



Supplementary Figure 1D

